ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500™

On November 25, 2020 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, reported it ranked 240 on Deloitte’s Technology Fast 500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year (Press release, ImmunoPrecise Antibodies, NOV 25, 2020, View Source [SID1234571743]). ImmunoPrecise grew 475% during this period.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ImmunoPrecise’s chief executive officer, Dr. Jennifer Bath, credits the onboarding of new clients and larger contract sizes with the company’s 475 percent revenue growth. "We continue to rapidly grow our customer base", stated Dr. Bath. "With hundreds of clients, including well over half of the world’s top 20 pharma, many continue to expand both the number of programs outsourced to IPA as well as the scope of each program, selecting from a diverse set of powerful discovery technologies."

"For more than 25 years, we’ve been honoring companies that define the cutting edge and this year’s Technology Fast 500 list is proof positive that technology — from software and digital media platforms, to biotech — truly does permeate so many facets of our lives," said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. "We congratulate this year’s winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic."

"Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer and more productive," said Mohana Dissanayake, partner, Deloitte & Touche LLP, and industry leader for technology, media and telecommunications, within Deloitte’s audit and assurance practice. "We extend sincere congratulations to these well-deserved winners — who all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible."

Overall, 2020 Technology Fast 500 companies achieved revenue growth ranging from 175% to 106,508% from 2016 to 2019, with median growth of 450%.

About Deloitte’s 2020 Technology Fast 500
Now in its 26th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

Axial Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

On November 25, 2020 Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, reported that company management will present at the virtual Piper Sandler 32 nd Annual Healthcare Conference taking place November 30 – December 3, 2020 (Press release, Axial Biotherapeutics, NOV 25, 2020, View Source [SID1234571742]). The presentation will be available for registered attendees via the Piper Sandler conference site.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Arvinas to Participate in Upcoming Virtual Investor Conferences

On November 25, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in two upcoming virtual investor conferences (Press release, Arvinas, NOV 25, 2020, View Source [SID1234571717]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020. A pre-recorded fireside chat held with John Houston, Ph.D., President and Chief Executive Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, is available here and on the Events + Presentations section of the Company’s website.

3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020. Ian Taylor, Ph.D., Chief Scientific Officer, and Randy Teel, Ph.D., Vice President of Corporate Development, will participate in a fireside chat at 8:50 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

On November 25, 2020 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that Richard Murray, Ph.D., chief executive officer and president, and Elizabeth Trehu, M.D., chief medical officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference (Press release, Jounce Therapeutics, NOV 25, 2020, View Source [SID1234571716]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded fireside chat will be available beginning on Tuesday, December 1, 2020 at 8:00 a.m. ET and can be viewed by visiting "Events & Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days.

TRILLIUM THERAPEUTICS TO PRESENT CLINICAL DATA AT THE 62ND AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

On November 25, 2020 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported the presentation of clinical data at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, which is being held virtually from December 5-8, 2020 (Press release, Trillium Therapeutics, NOV 25, 2020, View Source [SID1234571715]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TTI-622: Poster Presentation, Publication Number 1191

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I

Date: Saturday, December 5, 2020; available from 10:00AM EST

TTI-621: Oral Presentation, Publication Number 646

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
Presenter: Steven M. Horwitz, M.D., Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Immunotherapy in T/NK Cell Lymphoma

Date: Monday, December 7, 2020; Presentation at 3:00PM EST

The presentations will be available in the Events & Presentations section of Trillium’s website once released by the American Society of Hematology (ASH) (Free ASH Whitepaper).

Trillium will host a conference call on Monday, December 7th at 4:30PM EST.